---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003665"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:48:35.065246+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "low"
source: SEC EDGAR
---

# Ovid Therapeutics reduces workforce 20%, extends cash runway beyond 2024; OV329 on track for 2022 clinical entry

## Summary
- Workforce reduced by ~20% to extend cash runway beyond 2024 as part of organizational restructuring.
- OV329, a GABA aminotransferase inhibitor, expected to enter clinical trials in 2022 for tuberous sclerosis seizures.
- Takeda to present pivotal Phase 3 soticlestat results in Dravet and Lennox-Gastaut syndromes in 2023.
- Financial results for Q4/FY2021 reported but specific figures not provided in filing excerpt; focus on cost reduction.

## SEC filing metadata
- accession: 0000950170-22-003665
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000095017022003665/0000950170-22-003665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000095017022003665/ovid-20220315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003665
- JSON: https://secwatch.observer/filing/0000950170-22-003665.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.